Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition By Guy Webber Intelligent application of early in vitro testing can help mitigate major drug development risks. The pharmaceutical industry is inherently risky. To develop a molecule that has a desired, efficacious but yet safe effect in… Read More
Spheroids Rapidly Becoming a Preferred 3D Cell Culture Format By Dr John Comley There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D cell culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they offer an… Read More
The Discoverome - Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and… Read More
Immuno-Oncology's Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs… Read More
Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. Read More
A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the… Read More
Automated Liquid Handler Vendor vs Third Party Plastic Company by Dr John Comley Competing for the disposable pipette tip business. Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a 'compatible' product from a third party plastics… Read More
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians… Read More
3D Cellular Imaging - Advances and Considerations for High-Content Screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing… Read More
CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to… Read More
Ion Channels - Increasingly Enticing Targets For Drug Discovery by Dr Douglas Krafte and Deborah Erickson Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease. Pfizer Inc’s… Read More
By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More
Metabolomics - A Playbook for Functional Genomics By Dr David Ferrick If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily… Read More
By Dr John Comley High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, high content imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of… Read More
By Dr James Lim and Dr Fred Aswad While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results. This article discusses current attempts to make results from cell culture systems more biologically relevant which,… Read More
Microtissues For In Vitro Toxicity Assessment: Cost effective and in vivo relevant toxicology tools By Dr Stephanie Ravenscroft, Dr Caroline Bauch, Dr Laura Hinton and Dr Paul Walker Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to… Read More